ICD-10-CM Billable Code

C79.63

Secondary malignant neoplasm of bilateral ovaries

Clinical Classification Guidelines

Medical Intelligence & Overview

Secondary malignant neoplasm of bilateral ovaries, classified under ICD-10 code C79.63, refers to cancer that has spread (metastasized) to both ovaries from a primary site elsewhere in the body. This condition indicates advanced cancer cells originating from another organ, such as the breast, digestive system, or other tissues, have traveled through the bloodstream or lymphatic system and established new growths in both ovaries. Recognizing and diagnosing this condition is crucial in managing the underlying cancer effectively.

Causes & Symptoms

Clinical Causes: Spread of primary cancer from organs like the breast, gastrointestinal tract, or other pelvic structures Circulating cancer cells traveling through the bloodstream or lymphatic pathways Invasion of ovarian tissue by nearby or distant primary tumors Genetic factors may influence susceptibility to metastasis

Key Symptoms: Pelvic or abdominal pain or discomfort Enlargement or swelling of the abdomen Unexplained weight loss or gain Abdominal bloating or fullness Changes in bowel habits, including constipation or diarrhea Vaginal bleeding or discharge in some cases Feeling of heaviness or pressure in the pelvis

Diagnostic & Treatment

Diagnosis Path: Diagnosing secondary malignant neoplasm of bilateral ovaries involves a combination of clinical evaluation and diagnostic tests. Physicians may perform:

Treatment Protocols: Treatment strategies are tailored based on the primary cancer source, extent of spread, and overall health. Common approaches include:

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C79.63 a billable ICD-10 code?
Yes, C79.63 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C79.63?
Clinical documentation must specify the nature of Secondary malignant neoplasm of bilateral ovaries and any associated comorbidities for accurate reporting.

Cite this Clinical Reference